Tremfya (guselkumab subcutaneous injection) — Cigna

Initial criteria

• Patient age > 18 years; AND
• Medication prescribed by or in consultation with a rheumatologist or dermatologist

Reauthorization criteria

• Patient has been established on therapy (i.e., currently receiving Tremfya) and continues to derive benefit

Approval duration

initial 6 months, reauth 1 year